

Salicifarm 1000 mg/g powder for use in drinking water/milk for cattle and pigs

Authorised

- Sodium salicylate

Product identification

Medicine name:

Salicifarm 1000 mg/g powder for use in drinking water/milk for cattle and pigs

Active substance:

Sodium salicylate

Target species:

Cattle (calf)

Pig

Route of administration:

Oral use

Product details

Active substance and strength:

Sodium salicylate

1000.00 milligram(s) / 1.00 gram(s)

Pharmaceutical form:

Powder for use in drinking water/milk

Withdrawal period by route of administration:**Oral use:**

-

Cattle (calf)

- Meat and offal. no withdrawal period Zero days

-

Pig

- Meat and offal. no withdrawal period Zero days

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QN02BA04

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Hungary

Package description:

500 g container of high density polyethylene

1 kg container of high density polyethylene

1 kg multilayer bag (PET-aluminium-Polythene)

5 kg multilayer bag (PET-aluminium-Polythene)

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Generic application (Article 18 of Regulation (EU) 2019/6)

Marketing authorisation holder:

Chemifarma S.p.A.

Marketing authorisation date:

4/09/2025

Manufacturing sites for batch release:

Chemifarma S.p.A.

Responsible authority:

Directorate Of Veterinary Medicinal Products

Authorisation number:

This information is not available for this product.

Date of authorisation status change:

4/09/2025

Reference member state:

Netherlands

Procedure number:

NL/V/0432/001

Concerned member states:

Bulgaria Croatia Cyprus Czechia France Greece Hungary Italy Lithuania
Poland Portugal Romania

Generic of:

600000059248

To consult adverse reactions on veterinary medicinal products please go to
www.adrreports.eu/vet

Documents

Summary of Product Characteristics

Package Leaflet and Labelling

Public Assessment Report - Salicifarm - NL-V-0432-001-DC.pdf